Announces Pricing of Public Offering of Common Stock

Announces Pricing of Public Offering of Common Stock

YORK, NY - September 29, 2016 - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the

Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced

cancers, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to

the public of $1.25. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 1,200,000

shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about October 4, 2016,

subject to customary closing conditions.

gross proceeds to Actinium from this offering is expected to be $10,000,000, before deducting underwriting discounts and commissions

and other estimated offering expenses payable by Actinium. Actinium currently intends to use the net proceeds from the sale of

securities for general corporate purposes, including capital expenditures, the advancement of its drug candidates in clinical

trials, such as Iomab -B and Actimab - A, preclinical trials, and to meet working capital needs

Wainwright & Co. is acting as sole book-running manager for the offering. JonesTrading Institutional Services LLC is

acting as co-manager for the offering. Roth Capital is acting as a financial advisor for the offering.

offering is being conducted pursuant to a shelf registration statement that was previously filed with, and declared effective

by, the U.S. Securities and Exchange Commission ("SEC"). Prospective investors should read in their entirety the

prospectus supplement and the accompanying prospectus and the other documents that Actinium has filed with the SEC for more complete

information about Actinium and the offering. A prospectus supplement and accompanying prospectus relating to the offering

will be filed with the SEC and will be available free of charge on the website of the SEC at www.sec.gov. Electronic

copies of the preliminary prospectus supplement and accompanying prospectus and, when available, the prospectus supplement and

the accompanying prospectus may also be obtained from the offices of H.C. Wainwright & Co., LLC by emailing placements@hcwco.com.

press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein,

nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be

unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

Actinium Pharmaceuticals

Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted

payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on

its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta

emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate

Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred

to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory

or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product

candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the

age of 60 in a single-arm multicenter trial.

Statements for Actinium Pharmaceuticals, Inc.

news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995,

including statements regarding the closing of the offering and the anticipated use of proceeds. These statements are based on

management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from

those set forth in the statements. The forward-looking statements may include statements regarding product development, product

potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from

those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as

a result of new information, future events, or otherwise.

Pharmaceuticals, Inc.

Vice President, Finance and Corporate Development